| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/20/2005 | WO2004098627A9 Inhibition of platelet aggregation through acyclovir and two peptide antagonists |
| 01/20/2005 | WO2004096172A3 Vector for oral administration |
| 01/20/2005 | WO2004089981A3 Antitumor effect of mutant bik |
| 01/20/2005 | WO2004089407A3 Zwitterionic immunomodulators for the treatment of asthma and allergy |
| 01/20/2005 | WO2004087912A8 Inhibitor proteins of a protease and use thereof |
| 01/20/2005 | WO2004083382A3 Compositions and methods for treating hyperimmune response in the eye |
| 01/20/2005 | WO2004082608A3 Ligands for tgf-beta binding proteins and uses thereof |
| 01/20/2005 | WO2004082595A3 Therapeutic use of tumor necrosis factor-alpha mutein |
| 01/20/2005 | WO2004080467A3 Method of treating and preventing hyperparathyroidism with vitamin d2 or d4 compounds |
| 01/20/2005 | WO2004078783A3 Enzymes involved in apoptosis |
| 01/20/2005 | WO2004073625A3 Inhibitors of antigen presentation by mhc class ii molecules and methods of use thereof |
| 01/20/2005 | WO2004064758A3 Improved oral delivery of peptides |
| 01/20/2005 | WO2004034995A3 Methods and reagents for inducing immunity |
| 01/20/2005 | WO2004033479A3 Retroyclins: antiviral and antimicrobial peptides |
| 01/20/2005 | WO2004020466A8 Protein tyrosine phosphatase inhibitors |
| 01/20/2005 | WO2004015057A3 Mucin-immunoglobulin fusion proteins |
| 01/20/2005 | WO2004010848A3 Oncogenes useful for the identification of urinary bladder cancer |
| 01/20/2005 | WO2003099762A8 Agents and methods for the treatment of disorders associated with oxidative stress |
| 01/20/2005 | WO2003092727A9 Medical device |
| 01/20/2005 | WO2003082302A9 Bioadhesive directed somatic cell therapy |
| 01/20/2005 | WO2003066881A3 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 01/20/2005 | WO2003062392A3 Methods of treating conditions associated with an edg receptor |
| 01/20/2005 | WO2003026494A3 Galectins-1-and-4 in tumor development |
| 01/20/2005 | WO2002050289A8 Methods for the production of multimeric proteins, and related compositions |
| 01/20/2005 | US20050015820 Using transgenic mouse tissue as model for monitoring agents that affect appetite, energy expenditure and caloric and food intake; dietetics and weight gain |
| 01/20/2005 | US20050014835 Agents for Treating Diseases Caused by Nonsense Mutations |
| 01/20/2005 | US20050014742 Prevent binding to neuropeptide y; compound containing tertiary amidegroup |
| 01/20/2005 | US20050014738 Solid phase extraction; contacting with adsorption resin |
| 01/20/2005 | US20050014732 Combination of an aldosterone receptor antagonist and an anti-diabetic agent |
| 01/20/2005 | US20050014718 Tumor specific oligosaccharide sequences and use thereof |
| 01/20/2005 | US20050014711 Using oligonucleotide antibody |
| 01/20/2005 | US20050014710 Compositions and methods relating to prostate specific genes and proteins |
| 01/20/2005 | US20050014703 Cell differentiation, regeneration of epithelium pancreas cells into insulin producing beta-cells; administrering a peptidyl- peptidase activator |
| 01/20/2005 | US20050014701 Synergistic mixture; anticoagulants |
| 01/20/2005 | US20050014700 Cbi analogues of cc-1065 and the duocarmycins |
| 01/20/2005 | US20050014699 Combinations of enzyme inhibitor-containing preparations and the use thereof |
| 01/20/2005 | US20050014697 Reduce concentration of nitric oxide ; antiinflamamtory agents, stroke, antiproliferative agents; gastrointestinal disorders; inflammatory bowel disorders; antiarthritic agents; Parkinson's disease; Alzheimer's disease;amyotroic lateral sclerosis; anticancer agents |
| 01/20/2005 | US20050014696 Additive cytoprotective effects of two bioactive regions of pro-opiomelanocortin hormone |
| 01/20/2005 | US20050014695 Uses of a chemokine receptor able to bind to MCP-1, MIP-1 alpha and/or rantes |
| 01/20/2005 | US20050014694 to treat inflammatory, non-autoimmune central nervous system (CNS) diseases such as brain tumor, or central nervous system viral or bacterial infection,inhibit the activity of matrix metalloproteinases and suppress cytokine production by T lymphocytes |
| 01/20/2005 | US20050014693 Transmission and, or amplification of signals; oral or enteric administering, dissolving, absorption of peptide yy; obesity therapy |
| 01/20/2005 | US20050014692 Isolate nucleic acids; intensify stimulated insulin elimination; antidiabetic agents |
| 01/20/2005 | US20050014691 Ophthalmic compositions comprising trefoil factor family peptides |
| 01/20/2005 | US20050014690 Styryl acrylonitrile compounds and their use to promote myelopoiesis |
| 01/20/2005 | US20050014689 Remedies for life style-related diseases or cibophobia and method of screening the same |
| 01/20/2005 | US20050014688 Inducer of apoptosis |
| 01/20/2005 | US20050014687 Nucleoc acid sequences coding polypeptides; binding to antibodies; diagnosis, therapy of diseases such as cancer |
| 01/20/2005 | US20050014686 Somatostatin analogues |
| 01/20/2005 | US20050014685 Fungicide, microbiocide,glucanase inhibitor; therapy, prophylaxis of penumocystis infections in humans, animals |
| 01/20/2005 | US20050014684 Cycloheptatide; solid phase synthesis; anticancer agents |
| 01/20/2005 | US20050014683 Solvent extraction from plant |
| 01/20/2005 | US20050014682 Cell-free assay for insulin signaling |
| 01/20/2005 | US20050014681 Bioavailability; uniform dispersion, embedding polypeptide and water insoluble carrier |
| 01/20/2005 | US20050014680 Administering nuclear factor of activated T-cell agonist |
| 01/20/2005 | US20050014679 Genetic engineered insulin; antidiabetic agents |
| 01/20/2005 | US20050014675 Therapy for vascular system disease; using growth hormonr secretion promoter compound ; artheriosclerosis; cardiovascular disorders; anticholesterol agents |
| 01/20/2005 | US20050014264 Method of introducing siRNA into adipocytes |
| 01/20/2005 | US20050014258 Methods for altering cell fate |
| 01/20/2005 | US20050014242 Expression vector comprising nuclelotide sequences coding seriene protease for use as therapeutic protein in treatment of inflammatory, reproductive, epidermal and neurological tissue disorders |
| 01/20/2005 | US20050014241 Human glucose-6-phosphatase molecules and uses thereof |
| 01/20/2005 | US20050014240 Non-immunognic polyethylene glycol conjugated therapeutic uricase for use in treatment of kidney and inflammatory disorders |
| 01/20/2005 | US20050014229 Using transgenic animal to prepare osteoclastogenesis inhibitory factor (OCIF) for use in treatment of osteoporosis |
| 01/20/2005 | US20050014224 GITR ligand and GITR ligand-related molecules and antibodies and uses thereof |
| 01/20/2005 | US20050014222 Phosphatases which activate map kinase pathways |
| 01/20/2005 | US20050014220 Lectin-like domain of thrombomodulin and its therapeutic use |
| 01/20/2005 | US20050014194 Use of insulin response modulators in the treatment of diabetes and insulin resistance |
| 01/20/2005 | US20050014191 Transmembrane proteins for use in identifying modulator for treatment of inflammatory, splenic, bone, respiratory and cell proliferative disorders |
| 01/20/2005 | US20050014189 Expression vectors comprising gastrointestinal specific nucleotide sequences for use in detecting, diagnosing, classifying, monitoring, prognosticating, preventing or treating cell proliferative disorders of the gastrointestinal system |
| 01/20/2005 | US20050014187 Novel polypeptide hormone phosphatonin |
| 01/20/2005 | US20050014182 Use of calpain for identifying compounds that modulate pain |
| 01/20/2005 | US20050014181 Methods and compositions for the assessment of polymer assembly |
| 01/20/2005 | US20050014180 Growth differentiation factor-16 |
| 01/20/2005 | US20050014172 RNA interference mediated inhibition of muscarinic cholinergic receptor gene expression using short interfering nucleic acid (siNA) |
| 01/20/2005 | US20050014170 Using single nucleotide polymorphism as diagnostic/prognostic indicator of neuropsychiatric disorders; identifying modulators for treatment of psychological disorders |
| 01/20/2005 | US20050014158 Using presence of polymorphic sequences in gene associated with phospholipase to diagnose, prognose and treat non-insulin dependent diabetes mellitus and obesity |
| 01/20/2005 | US20050014152 Drug transporter and use thereof |
| 01/20/2005 | US20050013874 Suspension or particle-solvent mixture system of zinc-containing calcium phosphate microparticles and therapeutic agent for treating zinc deficiency |
| 01/20/2005 | US20050013872 Maintenance, regeneration; medical equipment such as stent, artificial heart; insertion into body |
| 01/20/2005 | US20050013867 Use of proton sequestering agents in drug formulations |
| 01/20/2005 | US20050013866 Particulate vectors for improving oral absorption of active principles |
| 01/20/2005 | US20050013864 In situ administering; mixture of bone morphogenic protein and ethylene oxide-propylene oxide copolymer |
| 01/20/2005 | US20050013855 siRNA associated with lipid precipitate; in vivo delivery to cytosol |
| 01/20/2005 | US20050013836 Antimicrobial flush solutions |
| 01/20/2005 | US20050013826 Administering modified protein having disruptive element located in internal region; enhancing ubiquitin proteasome system degradation; effective, long term T cell response |
| 01/20/2005 | US20050013825 Vaccine containing the catalytic subunit of telomerase for treating cancer |
| 01/20/2005 | US20050013824 Use of highly Immunodominant central nervous system myelin protein; inducing tolerance |
| 01/20/2005 | US20050013820 Methods and compositions for the treatment of MHC-associated conditions |
| 01/20/2005 | US20050013816 Antibodies or active fragments specific for MORT-1 (Mediator of Receptor Toxicity) protein having amino acid sequence 2; tumors, hiv |
| 01/20/2005 | US20050013815 Prevention and treatment of amyloidogenic disease |
| 01/20/2005 | US20050013814 Methods for treating rheumatoid arthritis using IL-17 antagonists |
| 01/20/2005 | US20050013813 Down Syndrome; and also include Alzheimer's Disease |
| 01/20/2005 | US20050013808 Nitroreductase enzymes |
| 01/20/2005 | US20050013801 Concurrently administering Interferon alpha and gamma; reducing incidence of complications |
| 01/20/2005 | US20050013800 Inhibiting ligand/receptor interactions involving immunoglobulins, interleukins, interferon-alpha, histamine and/or leukotrienes; long term relief; kits |
| 01/20/2005 | US20050013799 Using combination of IgE immunoglobulin inhibitor and antihistamine; kits |
| 01/20/2005 | US20050013796 Detection and treatment of breast disease |
| 01/20/2005 | DE10329847A1 Pharmazeutischer Wirkstoff gegen Prostatakarzinome A pharmaceutical agent against prostate cancer |
| 01/20/2005 | CA2532135A1 Biologically active substance of a vasoactive intestinal peptide for treating interstitial lung infections |
| 01/20/2005 | CA2531629A1 Medicinal composition containing nf-.kappa.b decoy for treating and preventing respiratory diseases and method of using the same |
| 01/20/2005 | CA2531623A1 Isolation of bone marrow fraction rich in connective tissue growth components and the use thereof to promote connective tissue formation |